Emicizumab prophylaxis: Prospective longitudinal real‐world follow‐up and monitoring-Reference-Cited by-同舟云学术

Emicizumab prophylaxis: Prospective longitudinal real‐world follow‐up and monitoring

Published:2021-04-23 Issue:3 Volume:27 Page:383-391
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Barg Assaf A.¹²^ORCID,Budnik Ivan³,Avishai Einat¹²,Brutman‐Barazani Tami¹²,Bashari Dalia¹,Misgav Mudi¹,Lubetsky Aaron¹,Kuperman Amir A.⁴⁵,Livnat Tami¹²^ORCID,Kenet Gili¹²^ORCID

Affiliation:

1. Sheba Medical Center National Hemophilia Center Tel Hashomer Israel

2. Amalia Biron Research Institute of Thrombosis and Hemostasis Sackler School of Medicine, Tel Aviv University Tel Aviv Israel

3. Department of Pathophysiology Sechenov First Moscow State Medical University (Sechenov University) Moscow Russia

4. Azrieli Faculty of Medicine Bar‐Ilan University Safed Israel

5. Blood Coagulation Service and Pediatric Hematology Clinic Galilee Medical Center Nahariya Israel

Funder

Roche

Publisher

Wiley

Subject

Genetics (clinical),Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hae.14318

Reference40 articles.

1. Prophylaxis usage, bleeding rates, and joint outcomes of hemophilia, 1999 to 2010: a surveillance project

2. Toward optimal therapy for inhibitors in hemophilia

3. Venous access in haemophilic children: choice and management

4. Inhibitors: our greatest challenge. Can we minimize the incidence?

5. Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emicizumab and unmet needs of patients with hemophilia a who are managed with replacement therapies;Expert Review of Hematology;2024-09-12

2. Predictive parameters for spontaneous joint bleeding during emicizumab prophylaxis;Blood Advances;2024-06-03

3. Emicizumab is well tolerated and effective in people with congenital hemophilia A regardless of age, severity of disease, or inhibitor status: a scoping review;Research and Practice in Thrombosis and Haemostasis;2024-05

4. Prophylaxis with emicizumab in children under 12 years old with haemophilia A without inhibitors in Uruguay: National experience;Haemophilia;2024-04-29

5. The foundation for investigating factor XI as a target for inhibition in human cardiovascular disease;Journal of Thrombosis and Thrombolysis;2024-04-25